Nj State Employees Deferred Compensation Plan Halozyme Therapeutics, Inc. Transaction History
Nj State Employees Deferred Compensation Plan
- $800 Million
- Q4 2024
A detailed history of Nj State Employees Deferred Compensation Plan transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Nj State Employees Deferred Compensation Plan holds 27,800 shares of HALO stock, worth $1.81 Million. This represents 0.17% of its overall portfolio holdings.
Number of Shares
27,800
Previous 27,800
-0.0%
Holding current value
$1.81 Million
Previous $1.59 Million
16.42%
% of portfolio
0.17%
Previous 0.19%
Shares
8 transactions
Others Institutions Holding HALO
# of Institutions
550Shares Held
124MCall Options Held
668KPut Options Held
259K-
Black Rock Inc. New York, NY17.6MShares$1.15 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$865 Million0.01% of portfolio
-
State Street Corp Boston, MA7.18MShares$468 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.17MShares$272 Million4.34% of portfolio
-
Bank Of America Corp Charlotte, NC3.45MShares$225 Million0.01% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.08B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...